Ignite Creation Date:
2024-05-06 @ 7:07 AM
Last Modification Date:
2024-10-26 @ 11:45 AM
Study NCT ID:
NCT02476968
Status:
COMPLETED
Last Update Posted:
2022-09-10
First Post:
2015-06-10
Brief Title:
To Assess the Efficacy and Safety of Olaparib Maintenance Monotherapy in the Treatment of Ovarian Cancer
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
An Open Label Single Arm Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza Olaparib Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy ORZORA
Status:
COMPLETED
Status Verified Date:
2022-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ORZORA
Brief Summary:
This is a prospective open-label single arm multi-center study to assess the real world clinical effectiveness and safety of olaparib maintenance monotherapy as the capsule formulation in line with the EU approved prescribing information and will be conducted in platinum-sensitive relapsed high grade epithelial ovarian cancer patients including patients with primary peritoneal and or fallopian tube cancer who carry germline or somatic BRCA mutations documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious known or predicted to be detrimentallead to loss of function
Detailed Description:
The study will recruit approximately 250 patients with sBRCAm disease or gBRCAm disease with the aim to accrue a minimum of 50 patients with sBRCAm disease
Patients with an unknown germline BRCA mutated status or gBRCAwt disease or previously identified as having a BRCAm disease by a tumour test will be considered for screening and will undergo upon informed consent signature central tumor and blood testing to determine their BRCA mutation status In addition to central BRCA testing patients screened for the study with unknown BRCA status or with known gBRCAwt status for whom an adequate archival tumour tissue sample is available will be tested for qualifying HRR gene alterations Patients confirmed to carry a deleterious or suspected deleterious BRCA-independent genetic alteration in any of 13 genes involved in the Homologous Recombination Repair HRR pathway HRRm cohort will be allowed into an additional exploratory cohort HRRm cohort It is expected that approximately 25 patients will be included in the HRRm cohort before the target number of 250 patients with BRCAm disease is reached
Patients will be assigned olaparib capsules orally 400 mg twice daily They should initiate olaparib treatment within 8 weeks after their last dose of platinum-containing chemotherapy last dose is the day of the last infusion and will be assessed every 4 weeks whilst on treatment
All patients will have clinical and objective radiological tumour assessments according to modified Response Evaluation Criteria in Solid Tumors RECIST 11 guidelines at baseline and every 12 weeks relative to date of enrolment until objective radiological disease progression as determined by the investigator Patients could continue to receive olaparib for as long as determined by the investigator until objective radiological disease progression or as long as in the investigators opinion they are benefiting from treatment in relation to other clinical assessments and they do not meet any other discontinuation criteria Once a patient has discontinued olaparib she will be managed as per local clinical practice but will remain in the study and data will be collected on subsequent treatments progression overall survival and safety
For exploratory analysis purposes patients will be asked to provide consent to
1 Optional tumour samples at baseline and at disease progression
2 An optional blood sample only for patients with a confirmed sBRCAm or HRRm disease
Patients with an unknown germline BRCA mutated status or gBRCAwt disease or previously identified as having a BRCAm disease by a tumour test will be considered for screening and will undergo upon informed consent signature central tumor and blood testing to determine their BRCA mutation status In addition to central BRCA testing patients screened for the study with unknown BRCA status or with known gBRCAwt status for whom an adequate archival tumour tissue sample is available will be tested for qualifying HRR gene alterations Patients confirmed to carry a deleterious or suspected deleterious BRCA-independent genetic alteration in any of 13 genes involved in the Homologous Recombination Repair HRR pathway HRRm cohort will be allowed into an additional exploratory cohort HRRm cohort It is expected that approximately 25 patients will be included in the HRRm cohort before the target number of 250 patients with BRCAm disease is reached
Patients will be assigned olaparib capsules orally 400 mg twice daily They should initiate olaparib treatment within 8 weeks after their last dose of platinum-containing chemotherapy last dose is the day of the last infusion and will be assessed every 4 weeks whilst on treatment
All patients will have clinical and objective radiological tumour assessments according to modified Response Evaluation Criteria in Solid Tumors RECIST 11 guidelines at baseline and every 12 weeks relative to date of enrolment until objective radiological disease progression as determined by the investigator Patients could continue to receive olaparib for as long as determined by the investigator until objective radiological disease progression or as long as in the investigators opinion they are benefiting from treatment in relation to other clinical assessments and they do not meet any other discontinuation criteria Once a patient has discontinued olaparib she will be managed as per local clinical practice but will remain in the study and data will be collected on subsequent treatments progression overall survival and safety
For exploratory analysis purposes patients will be asked to provide consent to
1 Optional tumour samples at baseline and at disease progression
2 An optional blood sample only for patients with a confirmed sBRCAm or HRRm disease
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None